NVCT vs TPR · $304.5M cap vs P/E 46, rev $8.00B
Nuvectis Pharma Inc (NVCT) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
NVCT does not have a complete income-statement cache yet.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
NVCT currently screens at market cap $304.5M. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the NVCT and TPR stock pages for the full models.
Not investment advice.